LINCOLN Lincoln Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall
Lincoln Pharmaceuticals reported a strong Q3 FY26, with double-digit growth in revenue, EBITDA, and net profit, driven by existing facilities and initial contributions from the Cepha block. The company is actively expanding its product portfolio, investing in a dedicated R&D center, and pursuing regulated market approvals in Canada and EU. While maintaining ambitious growth and margin targets, management acknowledged geopolitical and currency-related challenges.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 12.9%, net profit up 38.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 161 | 147 | 168 | 154 | 163 +1% | 166 +13% |
| EBITDA | 28 | 24 | 27 | 24 | 25 −11% | 24 +0% |
| Net profit | 26 | 21 | 12 | 28 | 20 −23% | 29 +38% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
